Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Other financing activities (2017 - 2020)

Historic Other financing activities for Takeda Pharmaceutical (TKPHF) over the last 4 years, with Q1 2020 value amounting to -$20.1 million.

  • Takeda Pharmaceutical's Other financing activities fell 11012.56% to -$20.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.6 million, marking a year-over-year decrease of 12011.65%. This contributed to the annual value of -$109.3 million for FY2025, which is 3961.97% up from last year.
  • Takeda Pharmaceutical's Other financing activities amounted to -$20.1 million in Q1 2020, which was down 11012.56% from -$15.5 million recorded in Q2 2019.
  • In the past 5 years, Takeda Pharmaceutical's Other financing activities ranged from a high of $25.1 billion in Q4 2017 and a low of -$21.9 million during Q2 2018
  • Moreover, its 4-year median value for Other financing activities was -$15.5 million (2019), whereas its average is $5.0 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Other financing activities soared by 2953.44% in 2019 and then tumbled by 11012.56% in 2020.
  • Takeda Pharmaceutical's Other financing activities (Quarter) stood at $25.1 billion in 2017, then crashed by 100.09% to -$21.9 million in 2018, then rose by 29.53% to -$15.5 million in 2019, then crashed by 30.28% to -$20.1 million in 2020.
  • Its Other financing activities was -$20.1 million in Q1 2020, compared to -$15.5 million in Q2 2019 and $198.9 million in Q1 2019.